![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2022
Krop, Ian E.; Im, Seock-Ah; Barrios, Carlos; Bonnefoi, Herve; Gralow, Julie; Toi, Masakazu; Ellis, Paul A.; Gianni, Luca; Swain, Sandra M.; Im, Young-Hyuck; De Laurentiis, Michelino; Nowecki, Zbigniew; Huang, Chiun-Sheng; Fehrenbacher, Louis; Ito, Yoshinori; Shah, Jigna; Boulet, Thomas; Liu, Haiying; Macharia, Harrison; Trask, Peter; Song, Chunyan; Winer, Eric P. und Harbeck, Nadia
(2022):
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
In: Journal of Clinical Oncology, Bd. 40, Nr. 5: S. 438-448
2021
O'Shaughnessy, Joyce; Schwartzberg, Lee; Piccart, Martine; Rugo, Hope S.; Yardley, Denise A.; Cortes, Javier; Untch, Michael; Harbeck, Nadia; Wright, Gail S.; Bondarenko, Igor; Glaspy, John; Nowecki, Zbigniew; Kayali, Fadi; Chan, Arlene; Levy, Christelle; Liu, Mei-Ching; Kim, Sung-Bae; Lemieux, Julie; Manikhas, Alexey; Tolaney, Sara; Lim, Elaine; Gombos, Andrea; Stradella, Agostina; Pegram, Mark; Fasching, Peter; Mangel, Laszlo; Semiglazov, Vladimir; Dieras, Veronique; Gianni, Luca; Danso, Michael A.; Vacirca, Jeff; Kroll, Stew; O'Connell, Joseph; Tang, Kevin; Wei, Thomas und Seidman, Andrew
(2021):
Results From CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane.
In: Clinical Advances in Hematology & Oncology, Bd. 19, Nr. 2: S. 12-13